Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BRAF mutation in thyroid cancer.

M Xing1

  • 1Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument St/Suite 333 Baltimore, MD 21287, USA. mxing1@jhmi.edu

Endocrine-Related Cancer
|June 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Later-Life Cognitive Trajectories and Risk of Death: Results from a 6-Year Longitudinal Study of 7082 Chinese.

The journal of prevention of Alzheimer's disease·2024
Same author

[Analysis of fast-growing culturable bacteria and pathogenic bacteria in the surface water of the northeast coast of Hainan Island in China].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2023
Same author

Exchange bias and Verwey transition in Fe<sub>5</sub>C<sub>2</sub>/Fe<sub>3</sub>O<sub>4</sub> core/shell nanoparticles.

Nanoscale·2021
Same author

[Serological study of Lyme disease antibody in 2 311 patients with arthritis symptoms in Hainan Province].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2021
Same author

Magnetic-field-induced self-assembly of FeCo/CoFe<sub>2</sub>O<sub>4</sub> core/shell nanoparticles with tunable collective magnetic properties.

Nanoscale·2021
Same author

Prognostic value of serum levels of soluble MICA (sMICA) in patients with prostate cancer.

British journal of biomedical science·2018
Same journal

The Role of the B7 Family in Autoimmune Thyroid Diseases and Thyroid Cancer.

Endocrine-related cancer·2026
Same journal

Lineage-Specific Steroidomic Signatures in Pituitary Neuroendocrine Tumors: Pregnenolone Enrichment in SF-1 Lineage and Associations with Tumor Behavior.

Endocrine-related cancer·2026
Same journal

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Endocrine-related cancer·2026
Same journal

The NET Score: An Interpretable AI-Assisted Prognostic Score for Mortality Risk in Lung Neuroendocrine Tumors.

Endocrine-related cancer·2026
Same journal

Intraprostatic steroid hormones and endocrine disruptors in prostate cancer.

Endocrine-related cancer·2026
Same journal

Functional Imaging in Hereditary Endocrine Neoplasms: Evolving Modalities and Clinical Implications.

Endocrine-related cancer·2026
See all related articles

The BRAF gene mutation is the most common genetic alteration in papillary thyroid cancer (PTC), driving tumor development and progression. This specific mutation serves as a diagnostic marker and indicates a poorer prognosis for thyroid cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genetic alterations are key drivers of thyroid cancer development and progression.
  • The BRAF gene mutation (T1799A transversion) is a significant recent discovery in thyroid cancer research.

Purpose of the Study:

  • To summarize the role of the BRAF mutation in thyroid tumorigenesis.
  • To highlight its significance as a diagnostic and prognostic marker.
  • To discuss potential therapeutic implications.

Main Methods:

  • Review of recent genetic findings in thyroid cancer.
  • Analysis of the prevalence and characteristics of the BRAF mutation.
  • Comparison with other genetic alterations like RET/PTC rearrangement.
  • Evaluation of BRAF mutation's impact on clinicopathological outcomes.

Related Experiment Videos

Main Results:

  • BRAF mutation is the most frequent genetic alteration in sporadic papillary thyroid cancers (PTCs), found in approximately 45%.
  • It is particularly prevalent in aggressive PTC subtypes and mutually exclusive with other common alterations.
  • The mutation is specific to PTC and PTC-derived anaplastic thyroid cancer, serving as a diagnostic marker.
  • BRAF mutation is linked to poorer clinicopathological outcomes, acting as an independent prognostic marker.

Conclusions:

  • The BRAF T1799A mutation is a crucial oncogenic driver in PTC.
  • It holds significant value as a diagnostic and prognostic biomarker for thyroid cancer.
  • Targeted therapies inhibiting the mitogen-activated protein kinase pathway are anticipated for BRAF-mutated thyroid cancers.